Author of

• 11794

  +

  P2.12 - Poster Session 2 - NSCLC Early Stage (ID 205)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11814

    +

    P2.12-020 - The Impact of Adjuvant Therapy in Resected Patients with Early Stage Non-Small Cell Lung Carcinoma: The ERCC1 and EGFR Expressions are Associated with Survival. (ID 2924)

    09:30 - 09:30  |  Author(s): A. Gürses
    • Abstract

    Background
    The aim of study was to investigate the impact of is searching effect of tumor ERCC-1 and EGFR expression levels on survival, metastasis and recurrence in patients with non-small cell lung cancer (NSCLC) who had undergone resectional surgery followed by adjuvant chemotherapy.

    Methods
    In this study, 140 patients with NSCLC who underwent resectional surgery between 2005 and 2009 were analyzed. The patients’ pTNM were constructed according to latest staging system and the specimens were analyzed by both conventional histopathological analysis (hematoxylin-eosin) and immunohistochemical staining for ERCC-1 and EGFR expression. Survival analysis was calculated according to Kaplan-Meier method.

    Results
    Thirtysix (25%) of patient had EGFR expression wheras and 98 (68%) patients were negative for EGFR. The 5-year survival rates of patients with or without EGFR expression were 52% and 54.8% respectively (p=0,717). In patients who had not adjuvant chemotherapy, the 5-year survival rates were 46.7% and 82.1% in patients with EGFR+ and EGFR- tumors respectively (*p=0.035). Tumor ERCC-1 expression level were evaluated in 128 patients. It was found that in 88 patients (61.1%) tumor showed ERCC-1 expression whereas no ERCC-1 expression was found in 40 patients (27.8%). We also found that 5-year survival rate was 65.2% in patients who had ERCC-1(+) tumors while it was 46.1% in patients with tumors not expressing ERCC-1(p=0.047).

    Conclusion
    ERCC-1 expression in tumor tissue seemed to be a good prognosticator in resected non-small cell lung cancer patients. On the other hand, EGFR expression indicated poor survival in these patients. Further studies are needed to clarify this issue.